Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the stock.

Oragenics Stock Up 5.1 %

NYSE:OGEN opened at $0.42 on Thursday. Oragenics has a 12-month low of $0.38 and a 12-month high of $7.74. The firm has a market capitalization of $2.34 million, a PE ratio of -0.05 and a beta of 0.50. The firm has a 50-day moving average price of $0.85 and a 200 day moving average price of $1.22.

Oragenics (NYSE:OGEN) last posted its quarterly earnings results on Friday, August 9th. The company reported ($0.51) earnings per share (EPS) for the quarter.

Institutional Trading of Oragenics

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC purchased a new stake in shares of Oragenics, Inc. (NYSE:OGEN) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned about 0.51% of Oragenics at the end of the most recent reporting period. Institutional investors and hedge funds own 18.71% of the company’s stock.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.